Evidence map›Paper›PMID 39748180›Full record

ArticleTransplantation2025

Where Are All the Clinical Trials for Chronic Rejection?

Paolo Cravedi, Umberto Maggiore, Paolo Molinari, Josh Levitsky, Emmanuel Zorn

Abstract read
In one paragraph

Article in Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paolo CravediDepartment of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY.
Umberto MaggioreNephrology Unit, University Hospital of Parma, Parma, Italy.
Paolo MolinariDepartment of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY.
Josh LevitskyDivision of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Emmanuel ZornDepartment of Medicine, Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY.

Funding

Innate B cell immunity and antibody-mediated rejection of human kidney allograftsR01AI123342 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Emmanuel Zorn · 2016 to 2026
$3.3M
Functional significance of plasma cell infiltrates of human cardiac allograft vasculopathyR01AI184963 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Emmanuel Zorn · 2025 to 2026
$1.5M
NIAID NIH HHS R01 AI123342NIAID NIH HHS R01 AI184963
6 · The paper itself

Abstract

Chronic rejection is arguably the main obstacle to long-term graft survival. Yet, clinical trials focusing on this condition are disappointingly scarce. Significant advances in treating chronic rejection cannot happen if there is no conduit for testing novel therapies. Here, we identified the main hurdles holding back clinical trials for chronic rejection and outlined a series of actions to address these roadblocks. We suggest that a new strategic plan combining expertise in basic and clinical research and leveraging complementary resources be launched to specifically target chronic rejection and achieve long-awaited progress. We only need the will.

Indexed as

Clinical Trials as TopicGraft RejectionGraft SurvivalImmunosuppressive AgentsOrgan TransplantationChronic DiseaseHumansTreatment OutcomeImmunosuppressive Agents

Identifiers

PMID39748180
PMCPMC12721027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.